Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 421

1.

Update on new biologics for intractable eosinophilic asthma: impact of reslizumab.

Sahota J, Robinson DS.

Drug Des Devel Ther. 2018 May 8;12:1173-1181. doi: 10.2147/DDDT.S109489. eCollection 2018. Review.

2.

A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial.

Hanratty CE, Matthews JG, Arron JR, Choy DF, Pavord ID, Bradding P, Brightling CE, Chaudhuri R, Cowan DC, Djukanovic R, Gallagher N, Fowler SJ, Hardman TC, Harrison T, Holweg CT, Howarth PH, Lordan J, Mansur AH, Menzies-Gow A, Mosesova S, Niven RM, Robinson DS, Shaw DE, Walker S, Woodcock A, Heaney LG; RASP-UK (Refractory Asthma Stratification Programme) Consortium.

Trials. 2018 Jan 4;19(1):5. doi: 10.1186/s13063-017-2384-7.

3.

Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study.

Bidder T, Sahota J, Rennie C, Lund VJ, Robinson DS, Kariyawasam HH.

Rhinology. 2018 Mar 1;56(1):42-45. doi: 10.4193/Rhin17.139.

PMID:
29288573
4.

Antidepressant Trials: Are the Diminishing Effect Sizes of Efficacy Trials Avoidable?

Rickels K, Robinson DS.

J Clin Psychopharmacol. 2017 Dec;37(6):648-650. doi: 10.1097/JCP.0000000000000796. No abstract available.

PMID:
29045306
5.

Phase three studies of biologics for severe asthma: could do better?

Robinson DS, Kariyawasam HH, Heaney LG.

Eur Respir J. 2017 Sep 12;50(3). pii: 1701108. doi: 10.1183/13993003.01108-2017. Print 2017 Sep. No abstract available.

6.

Exploiting members of the BAHD acyltransferase family to synthesize multiple hydroxycinnamate and benzoate conjugates in yeast.

Eudes A, Mouille M, Robinson DS, Benites VT, Wang G, Roux L, Tsai YL, Baidoo EE, Chiu TY, Heazlewood JL, Scheller HV, Mukhopadhyay A, Keasling JD, Deutsch S, Loqué D.

Microb Cell Fact. 2016 Nov 21;15(1):198.

7.

Assessing severe asthma.

Robinson DS.

Eur Respir J. 2016 Sep;48(3):611-3. doi: 10.1183/13993003.01034-2016. No abstract available.

8.

Mastering the prior authorization maze.

Robinson DS.

MGMA Connex. 2016 Apr;16(3):31-2. No abstract available.

PMID:
27220158
9.

Activin-A is overexpressed in severe asthma and is implicated in angiogenic processes.

Samitas K, Poulos N, Semitekolou M, Morianos I, Tousa S, Economidou E, Robinson DS, Kariyawasam HH, Zervas E, Corrigan CJ, Ying S, Xanthou G, Gaga M.

Eur Respir J. 2016 Mar;47(3):769-82. doi: 10.1183/13993003.00437-2015. Epub 2016 Feb 11.

10.

Albert Sjoerdsma.

Lovenberg WM, Robinson DS.

Neuropsychopharmacology. 2015 Dec;40(13):3061. doi: 10.1038/npp.2015.303. No abstract available.

11.

Fingerprints: A solution to protect your PHI.

Robinson DS.

MGMA Connex. 2015 Jul;15(5):22. No abstract available.

PMID:
26349106
12.

Mepolizumab for eosinophilic severe asthma: recent studies.

Robinson DS, Kariyawasam HH.

Expert Opin Biol Ther. 2015 Jun;15(6):909-14. doi: 10.1517/14712598.2015.1041911. Epub 2015 May 8. Review.

PMID:
25951938
13.

Safety and effect on reported symptoms of depigmented polymerized allergen immunotherapy: a retrospective study of 2927 paediatric patients.

Pfaar O, Sager A, Robinson DS.

Pediatr Allergy Immunol. 2015 May;26(3):280-286. doi: 10.1111/pai.12347.

14.

Depigmented-polymerised allergoids favour regulatory over effector T cells: enhancement by 1α, 25-dihydroxyvitamin D3.

Urry ZL, Richards DF, Black C, Morales M, Carnés J, Hawrylowicz CM, Robinson DS.

BMC Immunol. 2014 May 29;15:21. doi: 10.1186/1471-2172-15-21.

15.

Online virtual-patient cases versus traditional problem-based learning in advanced pharmacy practice experiences.

Al-Dahir S, Bryant K, Kennedy KB, Robinson DS.

Am J Pharm Educ. 2014 May 15;78(4):76. doi: 10.5688/ajpe78476.

16.

Inhaled allergen challenge in assessment of biologics for asthma.

Robinson DS.

Clin Exp Allergy. 2014 Jan;44(1):2-5. doi: 10.1111/cea.12234. No abstract available.

PMID:
24355015
17.

Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression.

Khan A, Sambunaris A, Edwards J, Ruth A, Robinson DS.

Int Clin Psychopharmacol. 2014 Mar;29(2):86-92. doi: 10.1097/YIC.0000000000000016.

18.

Depigmented-polymerized mixed grass/birch pollen extract immunotherapy is effective in polysensitized patients.

Pfaar O, Biedermann T, Klimek L, Sager A, Robinson DS.

Allergy. 2013 Oct;68(10):1306-13. doi: 10.1111/all.12219. Epub 2013 Sep 2.

PMID:
23991896
19.

Sublingual immunotherapy in allergic rhinitis: indications, efficacy and safety.

Kariyawasam HK, Rotiroti G, Robinson DS.

Rhinology. 2013 Mar;51(1):9-17. doi: 10.4193/Rhino11.268. Review.

PMID:
23441306
20.

Mepolizumab for severe eosinophilic asthma.

Robinson DS.

Expert Rev Respir Med. 2013 Feb;7(1):13-7. doi: 10.1586/ers.12.84.

PMID:
23362812
21.

Mepolizumab treatment for asthma.

Robinson DS.

Expert Opin Biol Ther. 2013 Feb;13(2):295-302. doi: 10.1517/14712598.2012.725717. Epub 2012 Sep 24.

PMID:
22998420
22.

A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy.

Pfaar O, Urry Z, Robinson DS, Sager A, Richards D, Hawrylowicz CM, Bräutigam M, Klimek L.

Allergy. 2012 Feb;67(2):272-9. doi: 10.1111/j.1398-9995.2011.02736.x. Epub 2011 Nov 23.

PMID:
22107266
23.

A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder.

Robinson DS, Kajdasz DK, Gallipoli S, Whalen H, Wamil A, Reed CR.

J Clin Psychopharmacol. 2011 Oct;31(5):643-6. doi: 10.1097/JCP.0b013e31822c6741.

PMID:
21869687
24.

Activin-A: a novel critical regulator of allergic asthma.

Kariyawasam HH, Semitekolou M, Robinson DS, Xanthou G.

Clin Exp Allergy. 2011 Nov;41(11):1505-14. doi: 10.1111/j.1365-2222.2011.03784.x. Epub 2011 Jun 1. Review.

PMID:
21631612
25.

A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder.

Khan A, Cutler AJ, Kajdasz DK, Gallipoli S, Athanasiou M, Robinson DS, Whalen H, Reed CR.

J Clin Psychiatry. 2011 Apr;72(4):441-7. doi: 10.4088/JCP.10m06596.

PMID:
21527122
26.

Utility of inhaled allergen challenge in clinical diagnosis and management of asthma: what never? Well, hardly ever!

Robinson DS.

Clin Exp Allergy. 2011 May;41(5):606-8. doi: 10.1111/j.1365-2222.2011.03736.x. No abstract available.

PMID:
21488992
27.

Treatment for asthma symptoms and prevalence of persistent asthma among children enrolled in Rhode Island's managed care Medicaid Program.

McQuade W, Pearlman DN, Robinson DS, Sutton N.

Med Health R I. 2011 Mar;94(3):78-80. No abstract available.

PMID:
21488531
28.

The role of the T cell in asthma.

Robinson DS.

J Allergy Clin Immunol. 2010 Dec;126(6):1081-91; quiz 1092-3. doi: 10.1016/j.jaci.2010.06.025. Epub 2010 Aug 14. Review.

PMID:
20709383
29.

Immunotherapy with depigmented-polymerized mixed tree pollen extract: a clinical trial and responder analysis.

Pfaar O, Robinson DS, Sager A, Emuzyte R.

Allergy. 2010 Dec;65(12):1614-21. doi: 10.1111/j.1398-9995.2010.02413.x.

PMID:
20645937
30.

Efficacy, safety, and immunological effects of a 2-year immunotherapy with Depigoid birch pollen extract: a randomized, double-blind, placebo-controlled study.

Höiby AS, Strand V, Robinson DS, Sager A, Rak S.

Clin Exp Allergy. 2010 Jul;40(7):1062-70. doi: 10.1111/j.1365-2222.2010.03521.x.

PMID:
20642579
31.

Four "lessons learned" while implementing a multi-site caries prevention trial.

Bader JD, Robinson DS, Gilbert GH, Ritter AV, Makhija SK, Funkhouser KA, Amaechi BT, Shugars DA, Laws R; X-ACT Collaborative Research Group.

J Public Health Dent. 2010 Summer;70(3):171-5. doi: 10.1111/j.1752-7325.2010.00167.x.

32.

Depigmented and polymerised house dust mite allergoid: allergen content, induction of IgG4 and clinical response.

Gallego MT, Iraola V, Himly M, Robinson DS, Badiola C, García-Robaina JC, Briza P, Carnés J.

Int Arch Allergy Immunol. 2010;153(1):61-9. doi: 10.1159/000301580. Epub 2010 Mar 31.

33.

CC chemokine receptor 4 (CCR4) in human allergen-induced late nasal responses.

Banfield G, Watanabe H, Scadding G, Jacobson MR, Till SJ, Hall DA, Robinson DS, Lloyd CM, Nouri-Aria KT, Durham SR.

Allergy. 2010 Sep;65(9):1126-33. doi: 10.1111/j.1398-9995.2010.02327.x. Epub 2010 Feb 10.

34.

Activin and transforming growth factor-beta signaling pathways are activated after allergen challenge in mild asthma.

Kariyawasam HH, Pegorier S, Barkans J, Xanthou G, Aizen M, Ying S, Kay AB, Lloyd CM, Robinson DS.

J Allergy Clin Immunol. 2009 Sep;124(3):454-62. doi: 10.1016/j.jaci.2009.06.022.

35.

Seasonal changes in suppressive capacity of CD4+ CD25+ T cells from patients with hayfever are allergen-specific and may result in part from expansion of effector T cells among the CD25+ population.

Anderson AE, Mackerness KJ, Aizen M, Carr VA, Nguyen D, Du Pre F, Durham SR, Robinson DS.

Clin Exp Allergy. 2009 Nov;39(11):1693-9. doi: 10.1111/j.1365-2222.2009.03320.x. Epub 2009 Jul 20.

PMID:
19622090
36.

Activin-A induces regulatory T cells that suppress T helper cell immune responses and protect from allergic airway disease.

Semitekolou M, Alissafi T, Aggelakopoulou M, Kourepini E, Kariyawasam HH, Kay AB, Robinson DS, Lloyd CM, Panoutsakopoulou V, Xanthou G.

J Exp Med. 2009 Aug 3;206(8):1769-85. doi: 10.1084/jem.20082603. Epub 2009 Jul 20.

37.

Regulatory T cells and asthma.

Robinson DS.

Clin Exp Allergy. 2009 Sep;39(9):1314-23. doi: 10.1111/j.1365-2222.2009.03301.x. Epub 2009 Jun 17. Review.

PMID:
19538496
38.

Comments on "Clinical trials of antidepressants: time to shift to a new model" by Dr Katz.

Rickels K, Robinson DS.

J Clin Psychopharmacol. 2009 Apr;29(2):197-8; author reply 198-9. doi: 10.1097/JCP.0b013e318199f275. No abstract available.

PMID:
19512995
39.

Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.

Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, Reed CR.

J Clin Psychiatry. 2009 Mar;70(3):326-33. Epub 2009 Mar 10.

PMID:
19284933
40.

Chemokine responsiveness of CD4+ CD25+ regulatory and CD4+ CD25- T cells from atopic and nonatopic donors.

Ahern D, Lloyd CM, Robinson DS.

Allergy. 2009 Aug;64(8):1121-9. doi: 10.1111/j.1398-9995.2008.01962.x. Epub 2009 Feb 7.

41.

Detection of allergen composition and in vivo immunogenicity of depigmented allergoids of Betula alba.

Carnés J, Himly M, Gallego M, Iraola V, Robinson DS, Fernández-Caldas E, Briza P.

Clin Exp Allergy. 2009 Mar;39(3):426-34. doi: 10.1111/j.1365-2222.2008.03132.x. Epub 2008 Dec 9.

PMID:
19134021
42.

New strategies for allergen immunotherapy.

Carnés J, Robinson DS.

Recent Pat Inflamm Allergy Drug Discov. 2008 Jun;2(2):92-101. Review.

PMID:
19075996
43.

CD4+CD25+ regulatory T cells reverse established allergic airway inflammation and prevent airway remodeling.

Kearley J, Robinson DS, Lloyd CM.

J Allergy Clin Immunol. 2008 Sep;122(3):617-24.e6. doi: 10.1016/j.jaci.2008.05.048. Epub 2008 Jul 30.

44.

Basal expression of bone morphogenetic protein receptor is reduced in mild asthma.

Kariyawasam HH, Xanthou G, Barkans J, Aizen M, Kay AB, Robinson DS.

Am J Respir Crit Care Med. 2008 May 15;177(10):1074-81. doi: 10.1164/rccm.200709-1376OC. Epub 2008 Feb 21.

PMID:
18292470
45.

Mortality risk in patients with schizophrenia participating in premarketing atypical antipsychotic clinical trials.

Khan A, Schwartz K, Stern C, Redding N, Kolts RL, Brown WA, Robinson DS.

J Clin Psychiatry. 2007 Dec;68(12):1828-33.

PMID:
18162012
46.

Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials.

Robinson DS, Gilmor ML, Yang Y, Moonsammy G, Azzaro AJ, Oren DA, Campbell BJ.

Psychopharmacol Bull. 2007;40(3):15-28.

PMID:
18007565
47.

The role of eosinophils in airway tissue remodelling in asthma.

Kariyawasam HH, Robinson DS.

Curr Opin Immunol. 2007 Dec;19(6):681-6. Epub 2007 Oct 22. Review.

PMID:
17949963
48.

Why do clinical trials fail?

Rickels K, Robinson DS.

J Clin Psychopharmacol. 2007 Aug;27(4):420-1; author reply 421. No abstract available.

PMID:
17632242
49.

Effect of inhaled interleukin-5 on eosinophil progenitors in the bronchi and bone marrow of asthmatic and non-asthmatic volunteers.

Menzies-Gow AN, Flood-Page PT, Robinson DS, Kay AB.

Clin Exp Allergy. 2007 Jul;37(7):1023-32.

PMID:
17581195
50.

The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability.

Robinson DS, Amsterdam JD.

J Affect Disord. 2008 Jan;105(1-3):15-23. Epub 2007 Jun 13. Review.

PMID:
17568687

Supplemental Content

Loading ...
Support Center